KRAS and colorectal carcinoma: NGS analysis of tissues from 430 patients with CRC showed that mutations in MAPK pathway genes (e.g., KRAS, NRAS, BRAF) and HER2 were significantly more frequent in MSI-H CRCs than in MSS tumors (83.6% vs. 58.4%, P = 0.0003) (66).